The cost-effectiveness of testing for hepatitis C in former injecting drug users

Health Technology Assessment

Volumn 10, Issue 32, 2006, Pages

  Castelnuovo, E ^a   Thompson Coon, J ^a   Pitt, M ^a   Cramp, M ^b   Siebert, U ^c   Price, A ^d   Stein, K ^a  

^a UNIVERSITY OF EXETER   (United Kingdom)

^b DERRIFORD HOSPITAL   (United Kingdom)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d Southampton Health Technology Assessments Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ALCOHOL CONSUMPTION; ANEMIA; ARTICLE; CASE FINDING; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DATA BASE; DEATH; DEPRESSION; DIAGNOSTIC VALUE; DISEASE COURSE; DRUG COST; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MISUSE; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; GENERAL PRACTICE; HEALTH CARE COST; HEALTH CARE POLICY; HEPATITIS C; HIGH RISK PATIENT; HUMAN; INSOMNIA; INTRAVENOUS DRUG ABUSE; LIVER BIOPSY; LIVER CANCER; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MORTALITY; MYALGIA; NATIONAL HEALTH SERVICE; NAUSEA; NEUTROPENIA; POLYMERASE CHAIN REACTION; PREVALENCE; PRIMARY PREVENTION; PRISON; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RIGOR; RISK FACTOR; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; UNITED KINGDOM; ADULT; COMPARATIVE STUDY; DECISION SUPPORT SYSTEM; DRUG DEPENDENCE TREATMENT; ECONOMICS; FEMALE; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; MIDDLE AGED; SUBSTANCE ABUSE; TREATMENT OUTCOME;

ADULT; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DISEASE PROGRESSION; FAMILY PRACTICE; FEMALE; GREAT BRITAIN; HEALTH CARE COSTS; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PRISONS; QUALITY-ADJUSTED LIFE YEARS; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME;

EID: 85044710392     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta10320     Document Type: Article

References (105)

1. Harris KA, Gilliam C, Mortimer PP, Teo CG. The most prevalent hepatitis C virus genotypes in England and Wales are 3a and 1a. J Med Virol 1999;58:127-31.
2. NIH Consensus Statement online. Management of hepatitis C. NIH Consensus Statement 105 [1997;15(3): 1-41. URL: http://odp.od.nih.gov/consensus/ cons/105/105-statement.htm
3. Delahooke TE. What is the nature of the problem? J Viral Hepat 2004; 11 Suppl 1:5-11.
4. El Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002;36:S74-83.
5. Llovet JM, Bustamante J, Castells A, Vilana R, Del Carmen Ayuso M, Sala M, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999;29:62-67.
6. Freeman AJ, Law MG, KaIdorJM, Dore GJ. Predicting progression to cirrhosis in chronic hepatitis C virus infection. J Viral Hepat 2003; 10:285-93.
7. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349:825-32.
8. Dore GJ, Freeman AJ, Law M, KaIdor JM. Natural history models for hepatitis C-related liver disease: different disease progression parameters for different settings. Antivir Ther 2003;8:365-72.
9. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C [see comment]. J Hepatol 2001;34:730-9.
10. Shiffman ML. Natural history and risk factors for progression of hepatitis C virus disease and development of hepatocellular cancer before liver transplantation. Liver Transpl 2003;9:S14-20.
11. Adinoffi LE, Utili R, Andreana A, Tripodi ME, Rosario P, Mormone G, et al. Relationship between genotypes of hepatitis C virus and histopathological manifestations in chronic hepatitis C patients. Eur J Gastroenterol Hepatol 2000;12:299-304.
12. Roffi L, Redaelli A, Colloredo G, Minola E, Donada C, Picciotto A, et al. Outcome of liver disease in a large cohort of histologically proven chronic hepatitis C: Influence of HCV genotype. Eur J Gastroenterol Hepatol 2001;13:501-6.
13. Verucchi G, Calza L, Manfredi R, Chiodo F. Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management. Infection 2004;32:33-46.
14. Sterling RK, Sulkowski MS. Hepatitis C virus in the setting of HIV or hepatitis B virus coinfection. Semin Liver Dis 2004;24 Suppl 2:61-8.
15. Department of Health. Hepatitis C Strategy for England. London: Department of Health; 2002.
16. Health Protection Agency. Supplementary data tables of the Unlinked Anonymous Survey of Injecting Drug Users in contact with services: data to the end of 2003. London: Department of Health; 2004.
17. Hahn JA, Page-Shafer K, Lum PJ, Bourgois P, Stein E, Evans JL, et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis 2002; 186:1558-64.
18. Hay G, McKeganey N, Hutchinson SJ, on behalf of the project team. Estimating the national and local prevalence of problem drug misuse in Scotland. London: Health Protection Agency Centre for Infections. Scottish Centre for Infection and Environmental Health. 2001.
19. Bird SM, Hutchinson SJ, Goldberg DJ. Drug-related deaths by region, sex, and age group per 100 injecting drug users in Scotland, 2000-01. Lancet 2003;362:941-4.
20. Frischer M, Heathe H, Hickman M. Estimating the prevalence of problematic and injecting drug use for Drug Action Team areas in England: a feasibility study using the Multiple Indicator Method. Home Office Online Report 34/04. London: Home Office; 2004.
21. Hickman M, Higgins V, Hope V, Bellis M, Tilling K, Walker A, et al. Injecting drug use in Brighton, Liverpool, and London: best estimates of prevalence and coverage of public health indicators. J Epidemiol Community Health 2004;58:766-71.
22. Johnson AM, Mercer CH, Erens B, Copas AJ, McManus S, Wellings K, et al. Sexual behaviour in Britain: partnerships, practices, and HIV risk behaviours. Lancet 2001;358:1835-42.
23. Bird SM, Goldberg DJ, Hutchinson SJ. Projecting severe sequelae of injection-related hepatitis C virus epidemic in the UK Part 2: preliminary UK estimates of prevalent injection-related hepatitis C carriers, and derivation of progression rates to liver cirrhosis by gender and age at hepatitis C virus infection. J Epidemiol Biostat 2001;6:267-77.
24. De Angelis D, Hickman M, Yang S. Estimating long-term trends in the incidence and prevalence of opiate use/injecting drug use and the number of former users: back-calculation methods and opiate overdose deaths. AmJ Epidemiol 2004; 160:994-1004.
25. Judd A, Hickman M, Jones S, McDonald T, Parry JV, Stimson GV, et al. Incidence of hepatitis C virus and HIV among new injecting drug users in London: a prospective cohort study. BMJ 2005;330:24-5.
26. Department of Health. Hepatitis C Action Plan for England. London: Department of Health; 2004.
27. Consensus Conference on Hepatitis C. Royal College of Physicians of Edinburgh Consensus Statement. J Viral Hepat 2004; 11 (Suppl 1): 2-4.
28. EASL International Consensus Conference on Hepatitis C. Paris, 26-28 February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol 1999;30:956-61.
29. Stein K, Dalziel K, Walker A, McIntyre L, Jenkins B, Horne J, et al. Screening for hepatitis C among injecting drug users and in genitourinary medicine clinics: systematic reviews of effectiveness, modelling study and national survey of current practice. Health Technol Assess 2002; 6:(31).
30. Bird SM, Goldberg DJ, Hutchinson SJ. Projecting severe sequelae of injection-related hepatitis C virus epidemic in the UK. Part 1: critical hepatitis C and injector data. J Epidemiol Biostat 2001;6:243-65.
31. Health Protection Agency, SCIEH, National Public Health Service for Wales, CDSC Northern Ireland, CRDHB, the UASSG. Shooting up; infections among injecting drug users in the United Kingdom 2003. London: Health Protection Agency; 2004.
32. Horne JA, Clements AJ, Drennan P, Stein K, Cramp ME. Screening for hepatitis C virus in the Dartmoor prison population: an observational study. J Public Health 2004;26:372-5.
33. Skipper C, Guy JM, Parkes J, Roderick P, Rosenberg WM. Evaluation of a prison outreach clinic for the diagnosis and prevention of hepatitis C: implications for the national strategy. Gut 2003;52:1500-4.
34. Department of Health. Models of care for the treatment of drug misusers; 2002. London: National Treatment Agency for Substance Misuse; 2002.
35. Wong J, Sylvestre D, Siebert U. Cost-effectiveness of treatment of hepatitis C in injecting drug users. In Jager J, Limburg W, Kretzschmar M, Postma M, Wiessing L, editors. Hepatitis C and injecting drug use: impact, costs and policy options. EMCDDA, Vol. 7. Lisbon: European Monitoring Centre for Drugs and Drug Addiction; 2004. pp. 219-41.
36. Colin C, Lanoir D, Touzet S, Meyaud-Kraemer L, Bailly E. Trepo C. Sensitivity and specificity of third-gcneration hepatitis C virus antibody detection assays: an analysis of the literature. J Viral Hepat 2001;8:87-95.
37. Booth JC, O'Grady J, Neuberger J. Clinical guidelines on the management of hepatitis C. Gut 2001;49 Suppl 1:11-21.
38. Ishak K, Baptista A, Bianchi L, Callea F, De GJ, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
39. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289-93.
40. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000;32:477-81.
41. Shepherd J, Waugh N, Hewitson P. Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review. Health Technology Assessment 2004;4(33).
42. Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2004;8:1-140.
43. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman ML, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa 2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
44. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alfa 2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
45. Wright M, Forton D, Main J, Goldin R, Torok E, Tedder R, et al. Treatment of histologically mild hepatitis C virus infection with interferon and ribavirin: a multicentre randomized controlled trial. J Viral Hepat 2005;12:58-66.
46. Chou R, Clark EC, Helfand M. Screening for hepatitis C virus infection: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2004;140:456-79.
47. Camma C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence based approach. J Hepatol 2001; 34:593-602.
48. Thompson Coon J, Ernst E. Complementary and alternative therapies in the treatment of chronic hepatitis C: a systematic review. J Hepatol 2004; 40:491-500.
49. Testa G, Crippin JS, Netto GJ, Goldstein RM, Jennings LW, Brkic BS, et al. Liver transplantation for hepatitis C: recurrence and disease progression in 300 patients. Liver Transpl 2000;6:553-61.
50. Neumann UP, Berg T, Bahra M, Puhl G, Guckelberger O, Langrehr JM, et al. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation 2004; 77:226-31.
51. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, Cabrera R, Shuster JJ, Theriaque D, et al. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl 2004;10:1240-7.
52. Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001;34:809-16.
53. McCusker M. Influence of hepatitis C status on alcohol consumption in opiate users in treatment. Addiction 2001;96:1007-14.
54. Gallegos-Orozco JF, Fuentes AP Gerardo AJ, Perez-Pruna C, Hinojosa-Becerril C, Sixtos-Alonso MS, et al. Health-related quality of life and depression in patients with chronic hepatitis C. Arch Aled Res 2003;34:124-9.
55. Bonkovsky H L, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology 1999;29:264-70.
56. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998;27:209-12.
57. Cordoba J, Flavia M, Jacas C, Saudela S, Esteban JI, Vargas V, et al. Quality of life and cognitive function in hepatitis C at different stages of liver disease. J Hepatol 2003;39:231-8.
58. Chong CA, Gulamhussein A, Heathcote EJ, Lilly L, Sherman M, Naglie G, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003;98:630-8.
59. Siebert U, Ravens-Sieberer U, Greiner W, Sroczynski G, Wong JB, Kuntz KM, et al. Performance of different utility assessment methods in chronic hepatitis C patients. In Kind P, Macran S, editors. Discussion papers. Centre for Health Economics, University of York: York; 2003.
60. van der Plas SM, Hansen BE, de Boer JB, Stijnen T, Passchier J, de Man RA, et al. Generic and disease specific health related quality of life in non-cirrhotic, cirrhotic and transplanted liver patients: a cross-sectional study. BMC Gastroenterol 2003;3:33.
61. McHutchison JG, Ware JE Jr, Bayliss MS, Pianko S, Albrecht JK, Cort S, et al. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 200 1;34:140-7.
62. Dalgard O, Egeland A. Skaug K, Vilimas K, Steen T. Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection. Hepatology 2004;39:74-80.
63. Loge JH, Kaasa S. Shortform 36 (SF-36) health survey: normative data from the general Norwegian population. Scand J Soc Med 1998;26:250-8.
64. Weild AR, Gill ON, Bennett D, Livingstone SJ, Parry JV, Curran L. Prevalence of HIV, hepatitis B, and hepatitis C antibodies in prisoners in England and Wales: a national survey. Commun Dis Public Health 2000;3:121-6.
65. Lamden KH, Kennedy N, Beeching NJ, Lowe D, Morrison CL, Mallinson H, et al. Hepatitis B and hepatitis C virus infections: risk factors among drug users in Northwest England. J Infect 1998;37:260-9.
66. Majid A, Holmes R, Desselberger U, Simmonds P, McKee TA. Molecular epidemiology of hepatitis C virus infection amongst intravenous drug users in rural communities. J Med Virol 1995;46:48-51.
67. Mohsen AH, Group TH, Trent HCV Study Group. The epidemiology of hepatitis C in a UK health regional population of 5.12 million. Gut 2001; 48:707-13.
68. Cramp ME, Rosenberg W. Guidance on the treatment of hepatitis C incorporating the use of pegylated interferons. London: British Society for Gastroentrology; 2003. URL: http://www.bsg.org.uk/pdf_word-docs/ pegylated-2003.doc
69. Irving WL. The role of the virology laboratory in the management of hepatitis C virus infection. J Clin Virol 2002;25:3-13.
70. Serfaty M, Lawrie A, Smith B, Brind AM, Watson JP, Gilvarry E, et al. Risk factors and medical follow-up of drug users tested for hepatitis C - can the risk of transmission be reduced? Drug Alcohol Rev 1997;16:339-47.
71. Jowett SL, Agarwal K, Smith BC, Craig W, Hewett M, Bassendine DR, et al. Managing chronic hepatitis C acquired through intravenous drug use. Qim 2001;94:153-8.
72. Smyth BP, Keenan E, O'Connor JJ. Assessment of hepatitis C infection in injecting drug users attending an addiction treatment clinic. Ir J Med Sci 2000;169:129-32.
73. Tiffen L, Sheridan S. Improving take-up of hepatitis C services. Nurs Times 2002;98(43): 30-32.
74. Poynard T, Ratziu V, Bedossa P. Appropriateness of liver biopsy. Can J Gastroenterol 2000;14: 543-8.
75. Foster GR, Goldin RD, Main J, Murray-Lyon I. Hargreaves S, Thomas HC. Management of chronic hepatitis C: clinical audit of biopsy based management algorithm. BMJ 1997;315:453-8.
76. National Institute of Clinical Excellence. Interferon alfa (pegylated and non pegylated) and ribavirin for the treatment of chronic hepatitis C. Technology Appraisal 75. London: NICE; 2004.
77. Beich A, Thorsen T, Rollnick S. Screening in brief intervention trials targeting excessive drinkers in general practice: a systematic review and meta-analysis. BMJ 2003;327:536-43.
78. Wright M, Grieve R, Roberts J, Main J, Thomas H, on behalf of the UK mild hepatitis C trial investigators. Health benefits of anti-viral therapy for mild chronic hepatitis C. Health Technol Assess 2006;10(21).
79. Dore GJ, Freeman AJ, Law M, Kaldor JM. Is severe liver disease a common outcome for people with chronic hepatitis C? J Gastroenterol Hepatol 2002;17:423-30.
80. Romeo R, Colombo M, Rumi M, Soffredini R, Del NE, Donato MF, et al. Lack of association between type of hepatitis C virus, serum load and severity of liver disease. J Viral Hepat 1996; 3:183-90.
81. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D, et al. Prognosis of chronic hepatitis C: results of a large prospective cohort study. Hepatology 1998;28:1687-95.
82. Benvegnu L, Noventa F, Bernardinello E, Pontisso P, Gatta A, Alberti A. Evidence for an association between the aetiology of cirrhosis and pattern of hepatocellular carcinoma development. Gut 2001;48:110-5.
83. Fattovich G, Giustina G, Degos E Tremolada. E, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-72.
84. Eattovich G, Giustina G, Degos F, Diodati G, Tremolada F, Nevens F, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. J Hepatal 1997;27:201-5.
85. Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, Christensen E. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 2002;97:2886-95.
86. Benvegnu L, Alberti A. Patterns of hepatocellular carcinoma development in hepatitis B virus and hepatitis C virus related cirrhosis. Antiviral Res 2001;52:199-207.
87. Bruno S, Silini E, Crosignani A, Borzio F, Leandro G, Bono F, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 1997; 25:754-8.
88. Serfaty L, Aumaitre H, Chazouilleres O, Bonnand A, Rosmorduc O, Poupon RE, et al. Determinants of outcome of compensated hepatitis C virus related cirrhosis. Hepatology 1998;27:1435-40.
89. Degos F, Christidis C, Ganne-Carrie N, Farmachidi J-P, Degott C, Guettier C, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000;47:131-6.
90. Transplant UK, Statistics and Audit Directorate. Transplant activity in the UK, 2003-2004. London: Transplant UK, Statistics and Audit Directorate; 2004.
91. Rodriguez-Luna H, Douglas DD. Natural history of hepatitis C following liver transplantation. Cur Opin Infect Dis 2004;17:363-71.
92. Neumann UP, Berg T, Bahra M, Seehofer D, Langrehr JM, Neuhaus R, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004;41:830-6.
93. Planas R, Balleste B, Alvarez MA, Rivera M, Montoliu S, Galeras JA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol 2004; 40:823-30.
94. Office for National Statistics. Cancer statistics registrations: registrations of cancer diagnosed in 2001, England. Series MBI No. 32. London: Office for National Statistics; 2004.
95. Office for National Statistics. Consumer Prices Index (CPI) 1988-2004, Monthly, First/News/Press Release, On-line edition. London: Office for National Statistics; 2004.
96. Home Office. Prison statistics England and Wales. Cm 5996. London: Home Office; 2002.
97. Edeh J, Spalding P. Screening for HIV, HBV and HCV markers among drug users in treatment in rural south-east England. J Public Health Med 2000;22:531-9.
98. Curtis L, Netten A. Unit costs of health and social care 2004. Canterbury: Nrsonal Social Services Research Unit; 2004.
99. British National Formulary. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain; 2004.
100. Ratcliffe J, Longworth L, Young T, Bryan S, Burroughs A, Buxton M. Assessing health-related quality of life pre- and post-liver transplantation: a prospective multicenter study. Liver Transpl 2002;8:263-70.
101. Claxton K, Ginnelly L, Sculpher M, Philips Z, Palmer S. A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment Programme. Health Technol Assess 2004;8(31).
102. Brennan A, Kharroubi S, O'Hagan A, Chilcott J. Calculating partial expected value of perfect information in cost-effectiveness models. School of Health and Related Research (ScHARR), University of Sheffield, 2002 (www.shef.ac.uk/content/l/c6/02/96/05/Brennan.doc).
103. Kaur S, Rybicki LB, Bacon B, Gollan J, Rustgi V, Carey W. Performance characteristics and results of a large-scale screening programme for viral hepatitis and risk factors associated with exposure to viral hepatitis B and C: results of the National Hepatitis Screening Survey. Hepatology 1996;24:979-86.
104. Gore SM, Bird AG, Cameron SO, Hutchinson SJ, Burns SM, Goldberg DJ. Prevalence of hepatitis C in prisons: WASH-C surveillance linked to self-reported risk bchaviours. QJM 1999;92: 25-32.
105. Ouzan D, Hoffiger P, Cavailler P, Mamino C, Tran A. Screening and hepatitis C management survey in general medicine in the Alpes-Maritime and East Var area. Gastroenterol Clin Biol 2003;27:90-3.